- Home
- FISI vs RGNX Comparison
FISI vs RGNX Comparison
Compare FISI & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FISI
- RGNX
- Stock Information
- Founded
- FISI 1817
- RGNX 2008
- Country
- FISI United States
- RGNX United States
- Employees
- FISI N/A
- RGNX N/A
- Industry
- FISI Major Banks
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FISI Finance
- RGNX Health Care
- Exchange
- FISI Nasdaq
- RGNX Nasdaq
- Market Cap
- FISI 500.2M
- RGNX 424.8M
- IPO Year
- FISI 1999
- RGNX 2015
- Fundamental
- Price
- FISI $25.78
- RGNX $8.82
- Analyst Decision
- FISI Buy
- RGNX Strong Buy
- Analyst Count
- FISI 3
- RGNX 8
- Target Price
- FISI $33.00
- RGNX $28.50
- AVG Volume (30 Days)
- FISI 133.9K
- RGNX 675.2K
- Earning Date
- FISI 07-24-2025
- RGNX 08-07-2025
- Dividend Yield
- FISI 4.77%
- RGNX N/A
- EPS Growth
- FISI N/A
- RGNX N/A
- EPS
- FISI N/A
- RGNX N/A
- Revenue
- FISI $102,639,000.00
- RGNX $155,782,000.00
- Revenue This Year
- FISI $122.14
- RGNX $327.08
- Revenue Next Year
- FISI $4.97
- RGNX N/A
- P/E Ratio
- FISI N/A
- RGNX N/A
- Revenue Growth
- FISI N/A
- RGNX 74.95
- 52 Week Low
- FISI $20.97
- RGNX $5.04
- 52 Week High
- FISI $29.79
- RGNX $13.48
- Technical
- Relative Strength Index (RSI)
- FISI 48.83
- RGNX 54.02
- Support Level
- FISI $24.62
- RGNX $7.35
- Resistance Level
- FISI $26.72
- RGNX $9.25
- Average True Range (ATR)
- FISI 0.78
- RGNX 0.54
- MACD
- FISI 0.09
- RGNX 0.08
- Stochastic Oscillator
- FISI 55.24
- RGNX 74.62
About FISI Financial Institutions Inc.
Financial Institutions Inc operates as a financial holding company, engages in the provision of a wide range of consumer and commercial banking services to individuals, municipalities, and businesses in Western and Central New York. It operates through one segment: The Banking segment which includes all of the company's retail and commercial banking operations.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.